Methods: The project was conducted in two phases. Phase one utilized a carrier test method against commonly encountered nosocomial pathogens over a 36-hour period to determine in vitro efficacy of the copper impregnated coating. A 10^7 CFU/mL suspension, supplemented with newborn calf serum for organic load, was used to inoculate all testing surfaces. Phase two, an in vivo study, was performed in several patient rooms in our hospital. In this phase, high touch surfaces were randomized to one of three surface treatment arms: 1) control A - no treatment; 2) control B - non-copper film; and 3) treatment - copper film. Quantitative aerobic colony counts were measured using a contact plate recovery method.
Results: In vitro testing revealed complete kill of MRSA and Acinetobacter baumanii on LDPE discs coated with the copper film at all tested time intervals (0.5, 1, 1.5, 2, 24 and 36 hours). In contrast, untreated discs yielded recovery of 10^3-10^4 CFU/mL over the same time intervals. In vivo testing in patient rooms prior to occupancy showed that average aerobic colony counts on high-touch surfaces treated with the copper-containing film were 43% lower than surfaces treated with a control (non-copper) film (0.27 CFU/cm^2 versus 0.47 CFU/cm^2).
Conclusion: Our studies show that the novel copper film surface treatment has rapid in vitro activity against a number of commonly encountered nosocomial pathogens. Initial findings from our in vivo studies demonstrate that the copper surface may have similar microbial activity when deployed in a real-world setting but additional data needs to be collected before this can be stated with greater certainty.
Engineered Materials, Inc.:
P. Varghese, None
K. Donaldson, Engineered Materials, Inc.: Employee , Salary
R. Tweed, Engineered Materials, Inc.: Employee , Salary